Bioregulators · Dosing reference

Cardiogen dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyCPreclinical researchNone established

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Not approved — research use only
Human amounts: None established in humans
Route studied: —
Frequency: Not established
Half-life: Not established
Evidence grade: Grade C · Preclinical research
Vial sizes on the market: 20 mg
Other forms seen: —

What Cardiogen is

A short synthetic bioregulator peptide, studied in research on cardiac tissue and cardiomyocyte biology.

No mechanism has been established. The organ-directed framing of the name comes from the programme in which these peptides were synthesised using peptide complexes extracted from particular organs as templates, and from an organotypic explant study in which cardiogen, bronchogen, prostamax and pancragen were each reported to stimulate growth of explants from the matching rat organ — heart, lung, prostate and pancreas… How it works →

Key evidence

Levdik and Knyazkin, Bulletin of Experimental Biology and Medicine · 2009 · Animals (senescent rats with transplanted M-1 sarcoma)
Tumour-cell apoptosis was higher after cardiogen injection than in control in all experimental groups, and inhibition of M-1 sarcoma growth was accompanied by haemorrhagic necrosis; proliferative-activity measures indicated the growth inhibition was not caused by direct cytostatic action, which the authors attributed to an effect on the tumour vasculature. ¹
Zakutskii et al., Advances in Gerontology (in Russian) · 2006 · Animal tissue ex vivo (organotypic explants of heart, lung, prostate and pancreas from 3-week-old and 18-month-old rats)
Each peptide, cardiogen included, was reported to stimulate growth in the matching tissue culture relative to control explants in both age groups. Available to this review only as an English abstract of a Russian-language paper. ²
Kheifets et al., Advances in Gerontology (in Russian) · 2010 · Cells (human prostate fibroblast cultures, early and late passage)
Cardiogen and the peptides T-32 and T-38 were reported to increase expression of CXCL12, WEDC1 and ghrelin in senescent cultures, with T-38 reported as the most active. Available to this review only as an English abstract of a Russian-language paper. ³

All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered Cardiogen. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for Cardiogen.

Cycle-length evidence for Cardiogen

Cardiogen draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

sizes on the market

2 · Water added

3 · Amount per draw

4 · Syringe

Your mix

20 mg + 2 mL water = 10 mg/mL

10 units holds 1 mg

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	40	—
1 mL	20	—
1.5 mL	13.33	—
2 mL	10	—
2.5 mL	8	—
3 mL	6.667	—
5 mL	4	—

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

Handling should follow the certificate of analysis and written documentation supplied with the specific lot; no stability or handling data specific to this compound were identified in the sources reviewed. Short lyophilised peptides are generally treated as hygroscopic, light-sensitive solids whose reconstituted solutions are chemically less stable than the dry material. Amiravo does not provide preparation, reconstitution or administration instructions.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: Not approved by the FDA for any use. An openFDA query on this name returns CardioGen-82, a rubidium Rb-82 generator approved under NDA019414, which is an unrelated radiopharmaceutical product and not this peptide ^8.
United States (FDA): There is no approved FDA application for this peptide. An openFDA Drug Label API query on the name returns CardioGen-82, a rubidium Rb-82 generator marketed by Bracco Diagnostics under NDA019414; that is an unrelated diagnostic radiopharmaceutical and not this peptide, and the similarity of names should not be read as any approval of the peptide ^8. Neither "cardiogen" nor "Ala-Glu-Asp-Arg" appears in any of the three categories of FDA's list of bulk drug substances nominated for use in compounding under section 503A of the FD&C Act, as updated 14 May 2026 ^10.
Sport (WADA): Not named in the WADA 2026 Prohibited List ^11. That absence is hedged negative evidence and not a clearance. Section S0 prohibits at all times "any pharmacological substance which is not currently approved by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use)" and states that the class "covers many different substances including but not limited to" its named examples; section S2 prohibits the listed peptide hormones, growth factors and mimetics "and other substances with similar chemical structure or similar biological effect(s)" ^11.

Status varies by country and changes over time. How we describe regulatory status.

Cardiogen compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
Cardiogen	Not approved — research use only	C	None established	—
Pinealon	Not approved — research use only	C	None established	—
Prostamax	Not approved — research use only	D	None established	—
Bronchogen	Not approved — research use only	C	None established	—
Cartalax	Not approved — research use only	D	None established	—
Pancragen	Not approved — research use only	B	None established	—

Frequently asked questions

What doses of Cardiogen have been studied in humans?

None that establish an amount. Cardiogen is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.

Is there an established Cardiogen cycle length?

No. We found no human studies that report treatment duration for Cardiogen.

How much bacteriostatic water should be added to a Cardiogen vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

Is Cardiogen FDA-approved?

Not approved — research use only. Not approved by the FDA for any use. An openFDA query on this name returns CardioGen-82, a rubidium Rb-82 generator approved under NDA019414, which is an unrelated radiopharmaceutical product and not this peptide ^8.

References

Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats Bulletin of Experimental Biology and Medicine. 2009
The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2006
Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging (in Russian) Advances in Gerontology (Uspekhi Gerontologii). 2010
US 7,662,789 B2 — Peptide substance restoring myocardium function (claims Ala-Glu-Asp-Arg; inventors Khavinson, Ryzhak, Grigoriev, Ryadnova) United States Patent and Trademark Office (granted patent). 2010
Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides Biochemistry (Moscow). 2013
PubMed query for "cardiogen" (81 records, of which three concern the peptide; most concern the unrelated French Cardiogen cardiac amyloidosis network) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026
PubChem compound name lookup for "Cardiogen" (resolves to CID 10917, L-carnitine — an unrelated homonym, not the peptide) PubChem, U.S. National Library of Medicine. 2026
openFDA Drug Label API query returning CardioGen-82 (rubidium Rb-82 generator, Bracco Diagnostics, NDA019414) — an unrelated product with a similar name U.S. Food and Drug Administration / openFDA. 2026
ClinicalTrials.gov registry query for "cardiogen" (4 records, all unrelated cardiovascular genetics and amyloidosis studies retrieved by name matching) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026
MeSH / NCBI Entrez query for "cardiogen" (0 records) Medical Subject Headings, U.S. National Library of Medicine. 2026

Last reviewed October 23, 2026 by the Amiravo editorial team. Editorial policy · Report an error